Oculis (NASDAQ:OCS) Sees Large Volume Increase – Here’s What Happened

Oculis Holding AG (NASDAQ:OCS) saw an uptick in trading volume on Tuesday . 1,245,505 shares changed hands during trading, an increase of 274% from the previous session’s volume of 332,726 shares.The stock last traded at $28.2620 and had previously closed at $27.42.

Analyst Upgrades and Downgrades

OCS has been the subject of several analyst reports. HC Wainwright increased their price objective on Oculis from $42.00 to $44.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Wall Street Zen downgraded Oculis from a “hold” rating to a “sell” rating in a research report on Saturday. Chardan Capital reiterated a “buy” rating and set a $51.00 price target on shares of Oculis in a report on Tuesday, November 11th. Lifesci Capital started coverage on Oculis in a research report on Wednesday, December 3rd. They set an “outperform” rating and a $55.00 price objective for the company. Finally, Needham & Company LLC boosted their price objective on shares of Oculis from $36.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.50.

Oculis Trading Up 5.3%

The company has a quick ratio of 5.96, a current ratio of 5.96 and a debt-to-equity ratio of 0.01. The business has a 50-day simple moving average of $26.31 and a 200-day simple moving average of $21.67. The company has a market cap of $1.67 billion, a PE ratio of -12.69 and a beta of 0.29.

Oculis (NASDAQ:OCS) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.08). Oculis had a negative return on equity of 62.12% and a negative net margin of 8,173.41%.The firm had revenue of $0.50 million for the quarter, compared to analysts’ expectations of $0.14 million. On average, analysts predict that Oculis Holding AG will post -2.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Oculis

Several institutional investors have recently bought and sold shares of OCS. China Universal Asset Management Co. Ltd. increased its stake in Oculis by 100.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock worth $40,000 after purchasing an additional 1,000 shares during the period. Aventura Private Wealth LLC purchased a new position in shares of Oculis in the fourth quarter valued at approximately $80,000. Millennium Management LLC acquired a new position in shares of Oculis in the fourth quarter valued at approximately $312,000. Bosun Asset Management LLC purchased a new stake in Oculis during the 2nd quarter worth approximately $378,000. Finally, Marshall Wace LLP purchased a new stake in Oculis during the 2nd quarter worth approximately $393,000. 22.30% of the stock is owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.